Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
about
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewBiologicals in rheumatoid arthritis: current and futureTargeting interleukin-6 for noninfectious uveitisIntegrating Interleukin-6 into depression diagnosis and treatmentSpotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to dateEmerging Therapies for Rheumatoid ArthritisPathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusAntibodies to watch in 2015Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.Investigational drugs in recent clinical trials for treatment-resistant depression.Chemokine receptors expression on peripheral CD4-lymphocytes in rheumatoid arthritis: Coexpression of CCR7 and CD95 is associated with disease activity.Brazilian Red Propolis Attenuates Inflammatory Signaling Cascade in LPS-Activated Macrophages.The Role of IL-17 and Th17 Lymphocytes in Autoimmune DiseasesTherapeutic antibodies that target inflammatory cytokines in autoimmune diseasesA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.Sirukumab: A Potential Treatment for Mood Disorders?IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.IL-6 blockade in chronic inflammatory diseases.Novel investigational drugs targeting IL-6 signaling for the treatment of depression.From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases.Novel treatment options for juvenile idiopathic arthritis.A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational studyB cells biology in systemic lupus erythematosus-from bench to bedside.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.The role of IL-6 in host defence against infections: immunobiology and clinical implications.Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Selected cytokine pathways in rheumatoid arthritis.Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery.Sirukumab: a promising therapy for rheumatoid arthritis.Role of Inflammation in Suicide: From Mechanisms to Treatment.A review on interleukins: The key manipulators in rheumatoid arthritis.Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
P2860
Q26769917-EA9D37CC-85E3-435A-B1BF-62EAF6FD9281Q26774874-80433A35-2AD7-4A13-8B0C-ECB47F1B06CFQ26780316-F7FB0609-3DC5-4DFA-BD47-F77C72DE8A7EQ26782493-F506F497-2EDB-499C-BF43-BF38F2B2C213Q28070891-DBE434BC-98A5-470F-9C02-B1CB1F90E096Q28076558-7DEB7A19-2C06-4731-BEB5-00845F915AB7Q28078943-705C136A-2356-41E8-8881-BD143BEA6551Q28088753-73C3306C-DC35-4DB4-B981-EF389B1B5BD9Q28253501-0F6A2936-2F66-421A-AE86-14FEAFD30081Q34465354-836CADE7-8EA1-4298-9560-83E514A66CB3Q34549390-96318EE6-71EF-4B4D-A954-98C2FBD1D6D9Q35804294-BA34AF6F-5807-40B9-919B-CF986157A144Q35867602-636A6BBF-1046-4248-A34D-BC038465D4DCQ36249305-EF2E9607-53B9-4B3A-878C-9CE31EF22EC3Q36958902-9D09766C-E08C-4233-97FA-524B6317077DQ37456300-F2C387AB-1B11-48F1-928A-FFE4B693E7E8Q37562443-68EAD000-21A3-4AF3-91F8-B5C19B14D10FQ38255855-87681AAA-47D2-4147-8649-0CCA6C5B837AQ38261783-B3E3B086-0B24-4126-BABF-0717CA4DEA0EQ38317241-297F1624-7B97-4FE2-8975-3DF49E5769ACQ38336406-E8435926-04D7-4977-AD7B-4B1AFDBEAFBFQ38371450-61594031-2206-40C0-97C3-D8FCBE566ABFQ38382090-C23106F7-3E7E-4C37-96A0-277B22AB9B26Q38570721-4469722C-EBC8-4BBF-B69F-C7D7B58FE2A0Q38628540-E11CF54D-86E2-4AEF-9BD7-35098063A2C7Q38631964-6843135E-D291-4117-9D76-A09456D761F2Q38685086-ECDE1454-713E-49DD-A95E-A428A81CEF46Q38697262-C65DCE61-7903-4851-A340-C1DBF9C44821Q38725223-2230A841-EDDA-4F0F-ADB0-B0A173E1D2E2Q38741139-D03775D1-CFB8-4C0F-BA1D-CC1C634329CDQ38745066-2B9BFAB6-554F-4E93-963A-5B4ECA790DDAQ38755912-6E177148-42BE-47FD-BCCA-79778C0020A5Q38759376-ADF16A41-5198-42D9-8F55-7AC9C7A92B65Q38838220-09345B99-030E-4BC6-B4D0-CDD6180B1445Q38856541-D7CC827C-8211-43A2-B893-429143B7BD63Q38856800-FFC4CAB3-477E-44DD-BDAE-E19B681C0030Q38885617-C805E0DC-00F3-4A27-B1F2-FDEC8EE7BD92Q39029629-97B695BE-32D1-4C85-A65D-07727F375FFAQ39068415-1EB3E39C-F429-407F-8C52-0E4395E192DDQ39176539-B8751444-2232-41ED-B5EC-E0E1AC5DF749
P2860
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@ast
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@en
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@nl
type
label
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@ast
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@en
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@nl
prefLabel
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@ast
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@en
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@nl
P2093
P2860
P921
P1476
Sirukumab, a human anti-interl ...... despite methotrexate therapy.
@en
P2093
Benjamin Hsu
Michael E Weinblatt
Shihong Sheng
Yanli Zhuang
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-205137
P407
P577
2014-04-03T00:00:00Z